PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33239432-3	2021	ORRs within the approved patient populations ranged from 64% (95% CI: 54, 73) in prior platinum treated RET fusion-positive NSCLC to 100% (95% CI: 63, 100) in systemic therapy naive RET fusion-positive thyroid cancer, with the majority of responders across indications demonstrating responses of at least 6 months.	Platinum	87-95	ret proto-oncogene	Homo sapiens	104-107	
34045295-3	2021	ORRs within the approved patient populations ranged from 57% (95% CI: 46, 68) in patients with RET fusion-positive NSCLC previously treated with platinum chemotherapy to 89% (95% CI: 52, 100) in patients with RET fusion-positive thyroid cancer, with response duration of at least 6 months in most responders.	Platinum	145-153	ret proto-oncogene	Homo sapiens	95-98	
24342537-6	2014	RESULTS: aPS/PT were found in 41.3% and 46.7% of SLE patients by the aPS/PT(ih) and the aPS/PT(c), respectively.	Platinum	13-15	ret proto-oncogene	Homo sapiens	92-97	
32846060-6	2020	RESULTS: In the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73).	Platinum	126-134	ret proto-oncogene	Homo sapiens	63-66	
28082048-13	2017	Four patients with tumors harboring CCDC6-RET and KIF5B-RET fusions showed pronounced and durable responses to platinum-based chemotherapy that lasted for 8 to 15 months.	Platinum	111-119	ret proto-oncogene	Homo sapiens	42-45	
28082048-13	2017	Four patients with tumors harboring CCDC6-RET and KIF5B-RET fusions showed pronounced and durable responses to platinum-based chemotherapy that lasted for 8 to 15 months.	Platinum	111-119	ret proto-oncogene	Homo sapiens	56-59	
25085632-0	2014	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent ) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.	Platinum	39-47	ret proto-oncogene	Homo sapiens	148-151